(thirdQuint)A Phase 3 Study With P2B001 in Subjects With Early Parkinson's.

 A total of 525 eligible subjects with early untreated Parkinson's disease (PD), will be randomized to 4 treatment groups.

 Each subject will participate in the study for approximately 18 weeks including a 30 day screening period, 12 week treatment period, and 2 weeks follow-up period.

.

 A Phase 3 Study With P2B001 in Subjects With Early Parkinson's@highlight

A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.

